Conference on abuse liability and appeal of tobacco products: Conclusions and recommendations

Drug and Alcohol Dependence

Volumn 116, Issue 1-3, 2011, Pages 1-7

  Henningfield, Jack E ^a,b   Hatsukami, Dorothy K ^c   Zeller, Mitch ^a   Peters, Ellen ^d  

^a PINNEY ASSOCIATES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Abuse liability; Abuse potential; Addiction; Appeal; Consumer; Dependence; Dose; Formulation; Ingredients; Marketing; Nicotine; Nicotine delivery; Policy; Product; Tobacco

Indexed keywords

PLACEBO;

ABUSE LIABILITY; ACCURACY; ADDICTION; ANALYTIC METHOD; CONSUMER; FACTORIAL ANALYSIS; FEASIBILITY STUDY; HEALTH HAZARD; HUMAN; MEDICAL EXPERT; NOTE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SOCIAL ASPECT; SOCIAL MARKETING; STANDARDIZATION; TOBACCO DEPENDENCE;

BEHAVIOR, ADDICTIVE; CONGRESSES AS TOPIC; CONSUMER SATISFACTION; HUMANS; MARKETING; NICOTINE; RESEARCH; TOBACCO; TOBACCO INDUSTRY; TOBACCO USE DISORDER; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

NICOTIANA TABACUM;

EID: 79957590836     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.12.009     Document Type: Note

References (59)

1. Anderson S.J., Ling P.M. " And they told two friends ... and so on": RJ Reynolds' viral marketing of Eclipse and its potential to mislead the public. Tob. Control 2008, 17:222-229.
2. Ashley D.L., Pankow J.F., Tavakoli A.D., Watson C.H. Approaches, challenges, and experience in assessing free nicotine. Nicotine Psychopharmacology, Handbook of Experimental Pharmacology 2009, vol. 192:437-456. Springer-Verlag, Berlin.
3. Balster R.L., Bigelow G.E. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend. 2003, 70(Suppl. 3):S13-S40.
4. Benowitz N.L., Hukkanen J., Jacob P. Nicotine chemistry, metabolism, kinetics and biomarkers. Nicotine Psychopharmacology, Handbook of Experimental Pharmacology 2006, vol. 192:29-60. Springer-Verlag, Berlin.
5. Carter L.P., Griffiths R.R. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend. 2009, 105(Suppl. 1):S14-S25.
6. Carter L.P., Stitzer M.L., Henningfield J.E., O'Connor R.J., Cummings K.M., Hatsukami D.K. Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiol. Biomarkers Prev. 2009, 18:3241-3262.
7. Conference of the Parties, 2010. Draft guidelines for the implementation of Articles 9 and 10 of the World Health Organization Framework Convention on Tobacco Control. World Health Organization, Geneva. Framework Convention on Tobacco Control. Fourth session, Punta del Este, Uruguay, November 2010, Agenda item 5.2. Available at (accessed 29.11.10). http://apps.who.int/gb/fctc/PDF/cop4/FCTC_COP4_6Rev1-en.pdf.
8. Dasgupta N., Schnoll S.H. Signal detection in post-marketing surveillance for controlled substances. Drug Alcohol Depend. 2009, 105(Suppl. 1):S33-S41.
9. Dart R.C. Monitoring risk: post marketing surveillance and signal detection. Drug Alcohol Depend. 2009, 105(Suppl. 1):S26-S32.
10. DeNoble V.J., Mele P.C. Intravenous nicotine self administration in rats: effects of mecamylamine, hexamethonium. Psychopharmacology 2006, 184:3-4.
11. Drug Enforcement Administration, 2010. Title 21 United States Code (USC) Controlled Substances Act. Available at: (accessed 13.07.10). http://www.deadiversion.usdoj.gov/21cfr/21usc/index.html.
12. Expert Panel Abuse liability assessment of CNS drugs: conclusions, recommendations, and research priorities. Drug Alcohol Depend. 2003, 70(Suppl. 3):S107-S114.
13. Farone, W.A., 2004. Written direct examination. United States of America v. Philip Morris. USA Inc., et al. Available at: (accessed 25.06.10). http://www.justice.gov/civil/cases/tobacco2/20040929%20Written%20Direct%20Testimony%20for%20William%20Farone%20PhD.pdf.
14. Food and Drug Administration Regulations restricting the sale and distribution of cigarettes and smokeless tobacco products to protect children and adolescents; proposed rule analysis regarding FDA's jurisdiction over nicotine-containing cigarettes and smokeless tobacco products; notice. Fed. Regist. 1995, 60:41314-41792.
15. Food and Drug Administration Regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents; final rule. Fed. Regist. 1996, 61:44396-45318.
16. Food and Drug Administration, 2010. Guidance for Industry: Assessment of Abuse Potential of Drugs. Draft Guidance. Available at: (accessed 24.06.10). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf.
17. Food and Drug Administration, 2010. Proposed cigarette product warning labels. Available at: (accessed 17.12.10). http://www.fda.gov/TobaccoProducts/Labeling/CigaretteProductWarningLabels/default.htm.
18. Grudzinskas C., Balster R.L., Gorodetzky C.W., Griffiths R.R., Henningfield J.E., Johanson C.E., Mansbach R.S., McCormick C.G., Schnoll S.H., Wright C. Impact of formulation on the abuse liability, safety, and regulation of medications: the expert panel report. Drug Alcohol Depend. 2006, 83(Suppl. 1):S77-S82.
19. Henningfield, J.E., 2004. Written direct testimony. United States of America v. Philip Morris. USA Inc., et al. United States Department of Justice. Available at: (accessed 29.06.10). http://www.justice.gov/civil/cases/tobacco2/Henningfield%20Written%20Direct.pdf.
20. Hilts P.J. Smokescre: The Truth Behind the Tobacco Industry Cover-up 1996, Addison-Wesley Publishing Company, Inc., Massachusetts.
21. Hoffman I., Hoffman D. The changing cigarette: chemical studies and bioassays. Tobacco: Science, Policy, and Public Health 2010, 93-125. Oxford University Press, Oxford. P. Boyle, N. Gray, J. Henningfield, J. Seffrin, W.A. Zatonski (Eds.).
22. Houtsmuller E.J., Fant R.V., Eissenberg T.E., Henningfield J.E., Stitzer M.L. Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacol. Biochem. Behav. 2002, 72:559-568.
23. Houtsmuller E.T., Henningfield J.E., Stitzer M.L. Subjective effects of the nicotine lozenge: assessment of abuse liability. Psychopharmacology 2003, 167:20-27.
24. Hurt R.D., Robertson C.R. Prying open the door to the tobacco industry's secrets about nicotine: the Minnesota Tobacco Trial. JAMA 1998, 280:1173-1181.
25. Johanson C.-E., Balster R.L., Henningfield J.E., Schuster C.R., Anthony J.C., Barthwell A.G., Coleman J.J., Dart R.C., Gorodetzky C.W., O'Keeffe C., Sellers E.M., Vocci F., Walsh S.L. Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: Expert Panel Report. Drug Alcohol Depend. 2009, 105(Suppl. 1):S65-S71.
26. Kessler D.A. A Question of Intent: A Great American Battle With a Deadly Industry 2001, Public Affairs, New York.
27. Ling P.M., Glantz S.A. Why and how the tobacco industry sells cigarettes to young adults: evidence from industry documents. Am. J. Public Health 2002, 92:908-916.
28. McColl F., Sellers E.M. Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend. 2006, 83(Suppl. 1):S52-S62.
29. Megerdichian C.L., Rees V.W., Wayne G.F., Connolly G.N. Internal tobacco industry research on olfactory and trigeminal nerve response to nicotine and other smoke components. Nicotine Tob. Res. 2007, 9:1119-1129.
30. National Cancer Institute, 2008. Monograph 19: The role of the media in promoting and reducing tobacco use. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. NIH Pub. No. 07-6242. U.S. Department of Health and Human Services, Bethesda, MD.
31. Okuyemi K.S., Lawrence D., Hammons G., Alexander L.A. Use of mentholated cigarettes: what can we learn from national data sets?. Addiction 2010, 105:1-4. 10.1111/j.1360-0443.2010.03239.x.
32. Pickworth W.B., Fant R.V., Butschky M.F., Henningfield J.E. Effects of transdermal nicotine delivery on measures of acute nicotine withdrawal. J. Pharmacol. Exp. Ther. 1996, 279:450-456.
33. Pierce J.P., Messer K., James L.E., White M.M., Kealey S., Vallone D.M., Healton C.G. Camel no. 9 cigarette-marketing campaign targeted young teenage girls. Pediatrics 2010, 125:619-626.
34. Rees V.W., Kreslake J.M., Cummings K.M., O'Connor R.J., Hatsukami D.K., Parascandola M., Shields P.G., Connolly G.N. Assessing consumer responses to potential reduced-exposure tobacco products: a review of tobacco industry and independent research methods. Cancer Epidemiol. Biomarkers Prev. 2009, 12:3225-3240.
35. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR), 2010. Addictiveness and attractiveness of tobacco additives. European Union, Brussels. Available at (accessed 29.11.10). http://ec.europa.eu/health/scientific_committees/consultations/public_consultations/scenihr_cons_12_en.htm.
36. Schuh K.J., Schuh L.M., Henningfield J.E., Stitzer M.L. Nicotine nasal spray and nicotine vapor inhaler: abuse liability determination. Psychopharmacology 1997, 130:352-361.
37. Schuster C.R., Henningfield J.E. Conference on abuse liability assessment of CNS drugs: introduction. Drug Alcohol Depend. 2003, 70(Suppl. 3):S1-S4.
38. Schuster C.R., Barthwell A.G., Henningfield J.E. Introduction to College on Problems of Drug Dependence special conference on risk management and post-marketing surveillance of CNS drugs. Drug Alcohol Depend. 2009, 105(Suppl. 1):S4-S8.
39. Schuster C.R., Henningfield J.E. Conference on abuse liability assessment of CNS drugs. Drug Alcohol Depend. 2003, 70(Suppl. 3):S1-S4.
40. Sellers E.M., Johanson C.-E. Drug formulation and abuse liability. Drug Alcohol Depend. 2006, 83(Suppl. 1):S1-S89.
41. Sellers E.M., Schuster C.R. Conference on drug formulations and abuse liability. Drug Alcohol Depend. 2006, 83(Suppl. 1):S1-S3.
42. Slade J., Bero L.A., Hanauer P., Barnes D.E., Glantz S.A. Nicotine and addiction: the Brown and Williamson documents. JAMA 1995, 274:225-233.
43. Slovic P. Smoking: Risk, Perception & Policy 2001, Sage, Thousand Oaks, CA.
44. Slovic P., Finucane M.L., Peters E., MacGregor D.G. Risk as analysis and risk as feelings: some thoughts about affect, reason, risk, and rationality. Risk Anal. 2004, 24:311-322.
45. Smith W.R. Product differentiation and market segmentation as alternative marketing strategies. J. Mark. 1956, 21:3-8.
46. Spillane J., McAllister W.B. Keeping the lid on: a century of drug regulation and control. Drug Alcohol Depend. 2003, 70(Suppl. 3):S5-S12.
47. Stratton K., Shetty P., Wallace R., Bondurant S. Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction 2001, National Academy Press, Washington, DC.
48. U.S. Congress, 2009. Family smoking prevention and tobacco control act. Public Law # 111-31. Available at (accessed 25.06.10). http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=111_cong_public_laws&docid=f:publ031.111.pdf.
49. U.S.Department of Health and Human Services The Health Consequences of Smoking: Nicotine Addiction. A Report of the Surgeon General 1988, United States Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health. U.S. Government Printing Office, Rockville, MD.
50. U.S.Department of Health and Human Services Preventing Tobacco use among Young People. A Report of the Surgeon General 1994, United States Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health. U.S. Government Printing Office, Rockville, MD.
51. United States District Court for the District of Columbia, 2006. Case 1:99-cv-02496-GK; United States of America vs. Philip Morris USA et al., Civil Action No. 99-2496 (GK). Final Opinion. Available at: (accessed 25.06.10). http://www.library.ucsf.edu/sites/all/files/ucsf_assets/FinalOpinion_full_version.pdf.
52. Watson C.H., Trommel J.S., Ashley D.L. A solid-phase microextraction approach to determine free-base nicotine in trapped mainstream cigarette smoke total particulate matter. J. Agric. Food Chem. 2004, 352:7240-7245.
53. Wayne G.F., Carpenter C.M. Manipulating product design to reinforce tobacco addiction. Tobacco: Science, Policy, and Public Health 2010, 171-195. Oxford University Press, Oxford. P. Boyle, N. Gray, J. Henningfield, J. Seffrin, W.A. Zatonski (Eds.).
54. Wayne G.F., Connolly G.N., Henningfield J.E. Assessing internal tobacco industry knowledge of the neurobiology of tobacco dependence. Nicotine Tob. Res. 2004, 6:927-940.
55. Wayne G.F., Connolly G.N., Henningfield J.E. Brand differences of free-base nicotine delivery in cigarette smoke: the view of the tobacco industry documents. Tob. Control 2006, 15:189-198.
56. Wayne F.E., Connolly G.N., Henningfield J.E., Farone W.A. Tobacco industry research and efforts to manipulate smoke particle size: implications for product regulation. Nicotine Tob. Res. 2008, 10:613-625.
57. World Health Organization Advancing Knowledge on Regulating Tobacco Products 2001, World Health Organization, Geneva.
58. World Health Organization Framework Convention on Tobacco Control 2005, World Health Organization, Geneva, Available at: http://www.who.int/fctc/en/ (accessed 16.11.10).
59. World Health Organization, 2007. The scientific bases of tobacco product regulation; Report of a WHO Study Group (TobReg). World Health Organization Technical Report Series, No. 945. World Health Organization, Geneva.